Molecular Subtyping of Stage I Lung Adenocarcinoma Via Molecular Alterations in Pre-invasive Lesion Progression

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2025 Mar 5

PMID 40038757

Authors

Jun Shang

He Jiang

Yue Zhao

Jingcheng Yang

Yicong Lin

Naixin Zhang

Luyao Ren

Qingwang Chen

Ying Yu

Leming Shi

Yuan Li

Haiquan Chen

Yuanting Zheng

Affiliations

Soon will be listed here.

Abstract

Background: Patients with adenocarcinoma in situ (AIS) and minimally invasive (MIA) lung adenocarcinoma (LUAD) are curable by surgery, whereas 20% stage I patients die within five years after surgery. We hypothesize that poor-prognosis stage I patients may exhibit key molecular characteristics deviating from AIS/MIA. Therefore, we tried to reveal molecularly and prognostically distinct subtypes of stage I LUAD by applying key molecular alterations from AIS/MIA to invasive LUAD progression.

Methods: The RNA and whole-exome sequencing data of 197 tumor-normal matched samples from patients with AIS, MIA, and invasive LUAD were analyzed. ddPCR quantified 202 samples from 182 patients at the absolute expression level. Immunohistochemical quantified the protein expression levels of ACTA2. RNA-seq data from 954 LUAD patients, including 541 stage I patients, along with 12 published datasets comprising 1,331 stage I LUAD patients, were used to validate our findings.

Results: Focal adhesion (FA) was identified as the only pathway significantly perturbed at both genomic and transcriptomic levels by comparing 98 AIS/MIA and 99 LUAD. Then, two FA genes (COL11A1 and THBS2) were found strongly upregulated from AIS/MIA to stage I while steadily expressed from normal to AIS/MIA. Furthermore, unsupervised clustering separated stage I patients into two molecularly and prognostically distinct subtypes (S1 and S2) based on COL11A1 and THBS2 expressions (FA2). Subtype S1 resembled AIS/MIA, whereas S2 exhibited more somatic alterations and activated cancer-associated fibroblast. Immunohistochemistry on 73 samples also observed that CAF was more active in S2 compared to S1 and AIS/MIA. The prognostic value of these two genes identified from our knowledge-driven process was confirmed by 541 stage I patients in a prospective dataset, ddPCR and 12 published datasets.

Conclusions: We successfully revealed two molecularly and prognostically distinct subtypes of stage I LUAD by applying key molecular alterations from AIS/MIA to invasive LUAD progression. Our model may help reliably identify high-risk stage I patients for more intensive post-surgery treatment.

References

Yotsukura M, Asamura H, Motoi N, Kashima J, Yoshida Y, Nakagawa K . Long-Term Prognosis of Patients With Resected Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma of the Lung. J Thorac Oncol. 2021; 16(8):1312-1320. DOI: 10.1016/j.jtho.2021.04.007. View

Bolger A, Lohse M, Usadel B . Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014; 30(15):2114-20. PMC: 4103590. DOI: 10.1093/bioinformatics/btu170. View

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X . A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res. 2010; 17(6):1490-501. PMC: 3079395. DOI: 10.1158/1078-0432.CCR-10-2703. View

Hanzelmann S, Castelo R, Guinney J . GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7. PMC: 3618321. DOI: 10.1186/1471-2105-14-7. View

Pignon J, Tribodet H, Scagliotti G, Douillard J, Shepherd F, Stephens R . Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26(21):3552-9. DOI: 10.1200/JCO.2007.13.9030. View

Racle J, de Jonge K, Baumgaertner P, Speiser D, Gfeller D . Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. 2017; 6. PMC: 5718706. DOI: 10.7554/eLife.26476. View

Tang H, Wang S, Xiao G, Schiller J, Papadimitrakopoulou V, Minna J . Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies. Ann Oncol. 2017; 28(4):733-740. PMC: 5834090. DOI: 10.1093/annonc/mdw683. View

Pertea M, Kim D, Pertea G, Leek J, Salzberg S . Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc. 2016; 11(9):1650-67. PMC: 5032908. DOI: 10.1038/nprot.2016.095. View

10.

Sturm G, Finotello F, Petitprez F, Zhang J, Baumbach J, Fridman W . Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics. 2019; 35(14):i436-i445. PMC: 6612828. DOI: 10.1093/bioinformatics/btz363. View

11.

Deng Y, Xia L, Zhang J, Deng S, Wang M, Wei S . Multicellular ecotypes shape progression of lung adenocarcinoma from ground-glass opacity toward advanced stages. Cell Rep Med. 2024; 5(4):101489. PMC: 11031428. DOI: 10.1016/j.xcrm.2024.101489. View

12.

Shen L, Yang M, Lin Q, Zhang Z, Zhu B, Miao C . COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance. Oncol Rep. 2016; 36(2):877-85. DOI: 10.3892/or.2016.4869. View

13.

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

14.

Kratz J, He J, Van Den Eeden S, Zhu Z, Gao W, Pham P . A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012; 379(9818):823-32. PMC: 3294002. DOI: 10.1016/S0140-6736(11)61941-7. View

15.

Wilkerson M, Hayes D . ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010; 26(12):1572-3. PMC: 2881355. DOI: 10.1093/bioinformatics/btq170. View

16.

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

17.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

18.

Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K . Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019; 16(12):1289-1296. PMC: 6884693. DOI: 10.1038/s41592-019-0619-0. View

19.

. A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium. Nat Biotechnol. 2014; 32(9):903-14. PMC: 4321899. DOI: 10.1038/nbt.2957. View

20.

Wu Y, Huang Y, Chang T, Chou C . Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-κB-mediated IKKβ expression. Int J Cancer. 2017; 141(11):2305-2317. DOI: 10.1002/ijc.30932. View